TScan Therapeutics Announces Upcoming Oral and Poster Presentations at the American College of Rheumatology Convergence 2025
TScan Therapeutics, Inc. (TCRX)
Company Research
Source: GlobeNewswire
WALTHAM, Mass., Sept. 17, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with cancer, today announced the acceptance of two abstracts, one as an oral presentation and another as a poster presentation, at the upcoming American College of Rheumatology (ACR) Convergence 2025 being held October 24 – 29 in Chicago, IL. “While we remain focused on oncology, our proprietary TargetScan technology is also well suited for identifying novel targets in T cell-driven autoimmune disorders,” said Gavin MacBeath, Ph.D., Chief Executive Officer. “We are excited to present our initial findings at the upcoming ACR Convergence. Among other discoveries, we believe we have identified several shared T-cell targets in Ankylosing Spondylitis. Therapeutic targets for AS have remained elusive despite decades of research and these r
Show less
Read more
Impact Snapshot
Event Time:
TCRX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TCRX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TCRX alerts
High impacting TScan Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TCRX
News
- TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market Opportunities [Yahoo! Finance]Yahoo! Finance
- TScan Therapeutics to Host Virtual KOL Event to Discuss Clinical Updates from the ALLOHA™ Phase 1 Trial and Future Market OpportunitiesGlobeNewswire
- TScan Therapeutics (NASDAQ:TCRX) was downgraded by analysts at Morgan Stanley from an "overweight" rating to an "equal weight" rating.MarketBeat
- TScan Therapeutics (NASDAQ:TCRX) had its price target lowered by analysts at HC Wainwright from $10.00 to $7.00. They now have a "buy" rating on the stock.MarketBeat
- TScan Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate UpdateGlobeNewswire
TCRX
Earnings
- 8/12/25 - In-Line
TCRX
Sec Filings
- 11/26/25 - Form 8-K
- 11/12/25 - Form 10-Q
- 11/12/25 - Form 8-K
- TCRX's page on the SEC website